ReWalk Robotics Q3 2023 revenue $4.4M (record), net loss $7.5M; AlterG acquisition closed

Lifeward Ltd.

2023-Q3 EPS reported -$0.28 revenue$6,970,000

Total revenue $4.4M, up 397% YoY; legacy ReWalk product revenue $1.5M (+65%), AlterG contributed $2.9M.
Net loss $7.5M ($0.13 per share) vs $5.5M ($0.09) in Q3 2022; adjusted net loss $4.5M ($0.08 per share).
Operating loss $7.9M; adjusted operating loss $4.9M, improving $0.2M vs prior year.
Completed AlterG acquisition for $19M cash on Aug 11, 2023; CMS finalized 2024 Home Health Rule including exoskeleton reimbursement.
Cash and equivalents $32.6M, no debt; cash used in operations $7.4M including $2.0M M&A costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lifeward Ltd. reported third quarter ended September 30, 2023 results: revenue $4.4 million, net income $7.5 million, or $(0.13) per share, EPS $(0.13) per share.

Period: third quarter ended September 30, 2023
Revenue: $4.4 million
Net income: $7.5 million, or $(0.13) per share
EPS: $(0.13) per share
Result: reported results

Exact text from the filing

Total revenue was $4.4 million in the third quarter of 2023, compared to $0.9 million during the third quarter of 2022

View on SEC.gov

47 earnings releases filed in the last 30 days. Browse all earnings releases →

Lifeward Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-23-003669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.